Encaptra® device

ViaCyte on the Rise: First Diabetes Trial Data & Acquires BetaLogics IP

VC-01-post-implant-final1-e1503703572933, viacyte

Clinical research on Type I Diabetes is one of the most exciting and promising areas of stem cells and regenerative medicine for human disease. Two of the coolest companies out there in this arena have been ViaCyte and BetaLogics (owned by J&J). For more on ViaCyte see my interview with President and CEO Paul Laikind …

ViaCyte on the Rise: First Diabetes Trial Data & Acquires BetaLogics IP Read More »

ViaCyte CEO Laikind Interview: Trial Update, Melton, & Future

VC-01-post-implant-final1-e1503703572933, viacyte

It’s been exciting to watch the recent developments in using stem cells as the basis for treatments for Type I Diabetes. One of the major players in this arena is the privately-held company, ViaCyte. In this post, I interview ViaCyte President and CEO, Paul Laikind. The topics include their VC-01 product, the Encaptra device, an update on …

ViaCyte CEO Laikind Interview: Trial Update, Melton, & Future Read More »

Great News: FDA Nod For ViaCyte IND of Diabetes Stem Cell-Based Product

ViaCyte-logo-3x2

Type 1 Diabetes is a huge global problem. Where are the solutions that would compliment or replace insulin therapy for diabetics? There haven’t been too many that have gotten very far, which makes the news of a potential stem cell-based therapy moving along in the pipeline all the more exciting. ViaCyte (see more posts here, …

Great News: FDA Nod For ViaCyte IND of Diabetes Stem Cell-Based Product Read More »